EBS Emergent BioSolutions Inc

NYSE
$5.50

Emergent BioSolutions Inc (EBS) is expected to report earnings on February 1, 2027, after the market close. The consensus earnings estimate is a loss of $0.19 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of -0.2% since its last earnings release on November 2, 2026.

Emergent BioSolutions Beat Consensus Estimates, Lowers Guidance
Monday, November 2, 2026 · 4:05 PM ET
Earnings Date
4th Quarter, Dec 2026
Feb 1
Monday · 4:05 PM ET
Earnings Whisper
-
vs ($0.19)
Rev est $138.76M
Volatility
Enter your expectations below to reveal the current volatility.
Trend Analysis
Expectation
Earnings
Price action
Signals
Score
Sentiment
Grade
Life Cycle
Call Analysis
Earnings-AVWAP $5.98

Sign in or subscribe to unlock sentiment, short interest, and technical indicators.

About Emergent BioSolutions Inc

Emergent BioSolutions Inc is a specialty biopharmaceutical company operating in two divisions: Biodefense and Biosciences. Its products include BioThrax, BAT, Anthrasil, VIGIV, RSDL, NuThrax, PreviThrax and GC-072.

Sector

Healthcare

Industry

Biotechnology

Held By 1 ETFs, by dollar flow

Charts powered in part by Lightweight Charts™ by TradingView.